Many studies have shown G-CSF mobilises CD34 + and CD133 + cells [26, 27] and clinical trials have investigated its therapeutic use in diseases such as cancer, stroke and liver failure, with mixed results [28–30]. This evidence concerns the gene PROM1 and stroke disorder.